Kerr on Oncology
David J. Kerr, MD, is a professor of cancer medicine at the University of Oxford in Oxford, England. He is recognized internationally for his work in the research and treatment of colorectal cancer, and has published more than 400 papers. He has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth and in 2010 was elected president of the European Society for Medical Oncology.+ Add to Email Alerts
- Colorectal Cancer On the Rise in Young Adults
- Aspirin Use Enhances Immunosurveillance in Colorectal Cancer
- Treating Patients With Cancer From Prison: A Complex Reality
- 'We're Just Not Doing It Right': Caring for Medical Students
- Guidelines Don’t Eliminate Variations in Chemotherapy Uptake
- Mapping a Positive Way Forward for Bowel Cancer Screening
- Weighing the Balance: Immunotherapy for Cancer Treatment
- How I Treated It: Colorectal Cancer During Pregnancy
- The Simple Change That Can Improve Patient Satisfaction
- Cancer Prevention Beliefs: Where Have We Gone Wrong?
- Truth vs TikTok: Cancer Diet Facts
- Oxaliplatin in Older Adults With Resected Colorectal Cancer?
- A Protocol for Vaccinating Patients With Lynch Syndrome
- Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer
- Trustworthy AI Can Be of Great Utility: Are We There?
- How Two Cancer Patients Found Joy at the End of Life
- New Research Points to a Better Biomarker for MSI mCRC
- Phase 1 Trials: Are We Using Optimal Drug Dose Schedules?
- AI in Oncology: Sorting Through Misinformation
- Health Professionals: Reducing the Risks for Nuclear War